1. Home
  2. WYNN vs RDY Comparison

WYNN vs RDY Comparison

Compare WYNN & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Wynn Resorts Limited

WYNN

Wynn Resorts Limited

HOLD

Current Price

$96.76

Market Cap

10.4B

ML Signal

HOLD

Logo Dr. Reddy's Laboratories Ltd

RDY

Dr. Reddy's Laboratories Ltd

HOLD

Current Price

$13.47

Market Cap

11.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WYNN
RDY
Founded
2002
1984
Country
United States
India
Employees
N/A
N/A
Industry
Hotels/Resorts
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.4B
11.6B
IPO Year
2002
2001

Fundamental Metrics

Financial Performance
Metric
WYNN
RDY
Price
$96.76
$13.47
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
14
1
Target Price
$144.43
$16.90
AVG Volume (30 Days)
1.9M
2.0M
Earning Date
05-05-2026
05-08-2026
Dividend Yield
1.03%
0.53%
EPS Growth
N/A
N/A
EPS
3.14
N/A
Revenue
$6,717,660,000.00
N/A
Revenue This Year
$6.35
$7.50
Revenue Next Year
$4.58
$2.96
P/E Ratio
$30.78
$18.67
Revenue Growth
10.67
N/A
52 Week Low
$65.25
$12.26
52 Week High
$134.72
$16.17

Technical Indicators

Market Signals
Indicator
WYNN
RDY
Relative Strength Index (RSI) 36.88 38.35
Support Level $96.37 $13.32
Resistance Level $111.94 $14.14
Average True Range (ATR) 3.36 0.23
MACD -0.03 -0.08
Stochastic Oscillator 7.73 7.66

Price Performance

Historical Comparison
WYNN
RDY

About WYNN Wynn Resorts Limited

Wynn Resorts operates luxury casinos and resorts. The company was founded in 2002 by Steve Wynn, the former CEO. The company operates four megaresorts: Wynn Macau and Encore in Macao and Wynn Las Vegas and Encore in Las Vegas. Cotai Palace opened in August 2016 in Macao, and Encore Boston Harbor in Massachusetts opened June 2019. We expect the company to continue to build nongaming attractions in Macao over the next few years. We model Wynn's managed integrated resort in the United Arab Emirates to open in 2027. The company received 49% and 51% of its 2025 prepandemic EBITDA from Macao and the US, respectively.

About RDY Dr. Reddy's Laboratories Ltd

Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.

Share on Social Networks: